KPRXライブシグナル | Getagraph.comで利益を最大化

買う 118003 min ago

@ $0.800

発行日: 8 2月 2024 @ 03:05

リターン: -40.63%

前回のシグナル: 2月 8 - 01:44

前回のシグナル: 売る

リターン: -5.88 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:34):

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States...

Stats
本日の出来高	117 982
平均出来高	1.71M
時価総額	12.47M
EPS	$-0.470 ( 2024-03-28 )
次の収益日	( $-0.420 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0.00400 (0.84%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-29	Tosca Melissa	Buy	60 000	Stock Option (right to buy)
2023-09-29	Tosca Melissa	Buy	30 000	Common Stock
2023-09-29	Daniels Eric Joseph	Buy	125 000	Stock Option (right to buy)
2023-09-29	Daniels Eric Joseph	Buy	62 500	Common Stock
2023-09-29	Strem Brian M.	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 1 933 640 \| Sell: 3 426 001

ボリューム相関

長: 0.18 (neutral)

短: 0.36 (neutral)

Signal:(47.521) Neutral

Kiora Pharmaceuticals, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kiora Pharmaceuticals, 相関 - 通貨/商品

-0.03
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.07
( neutral )

Kiora Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2023
収益:	$0
総利益:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2022
収益:	$0
総利益:	$-134 028 (0.00 %)
EPS:	$-18.55

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-143.31

Financial Reports:

No articles found.

Kiora Pharmaceuticals,

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.